To assess the effect of intermittent systemic therapy versus continuous systemic therapy in terms of survival, toxicity and quality of life in patients with unresectable metastatic colorectal cancer (CRC).
This is a protocol.
Cochrane
Trusted evidence.
Informed decisions.
Better health.